Hutchmed launches development programme for next-gen therapy platform
17th Dec 2025 17:08
(Sharecast News) - Hutchmed said on Wednesday that it has initiated a global phase one clinical development programme for HMPL-A251, marking the first clinical-stage candidate from its next-generation Antibody-Targeted Therapy Conjugate platform.
Read moreHutchmed medicines get renewed, new reimbursement coverage in China
8th Dec 2025 11:50
(Sharecast News) - Hutchmed China said on Monday that several of its oncology medicines would remain covered under China's state reimbursement system next year, while another had been added to a new commercial insurance list, expanding patient access and reinforcing the company's position in the country's multi-layered healthcare market.
Read moreHutchmed enrols last patient in phase three lung cancer trial
5th Nov 2025 14:22
(Sharecast News) - Hutchmed China said in an update on Wednesday that it has completed patient enrollment for its global phase three 'Saffron' trial evaluating the combination of Orpathys and Tagrisso in certain lung cancer patients with MET overexpression or amplification who had progressed following Tagrisso treatment.
Read moreHutchmed takes wraps off expanding oncology pipeline
3rd Nov 2025 12:00
(Sharecast News) - Hutchmed unveiled new details on its expanding oncology pipeline and research strategy, including the launch of its next-generation antibody-targeted therapy conjugate (ATTC) platform, during its annual research and development update on Monday.
Read moreHutchmed upbeat on preclinical data for novel cancer therapy
23rd Oct 2025 11:28
(Sharecast News) - Hutchmed China reported preclinical data on Thurdsay, showing strong anti-tumour activity for its novel cancer therapy HMPL-A251, the first investigational drug to emerge from the company's proprietary Antibody-Targeted Therapy Conjugate (ATTC) platform.
Read moreHutchmed to present new and updated clinical data
5th Sep 2025 09:45
(Sharecast News) - Hutchmed China said on Friday that new and updated clinical data from several of its drug candidates would be presented at two major oncology meetings this month, including the World Conference on Lung Cancer (WCLC) in Barcelona and the Chinese Society of Clinical Oncology (CSCO) annual meeting in Jinan.
Read moreHutchmed enrols last patient in phase 3 lung cancer trial
20th Aug 2025 09:16
(Sharecast News) - Hutchmed China said in an update on Wednesday that it has completed patient enrollment in its phase three 'Sanovo' trial in China testing a combination of 'Orpathys', or savolitinib, and 'Tagrisso', or osimertinib, as a first-line therapy for certain non-small cell lung cancer patients.
Read moreHutchmed to get milestone payment after China drug approval
30th Jun 2025 12:29
(Sharecast News) - Hutchmed announced on Monday that China's National Medical Products Administration (NMPA) has approved the new drug application for the combination of 'Orpathys'. Or savolitinib, and 'Tagrisso', or osimertinib, to treat patients with locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer (NSCLC) with MET amplification following progression on EGFR TKI therapy.
Read moreHutchmed new drug application accepted in China
5th Jun 2025 11:18
(Sharecast News) - Hutchmed China and Innovent Biologics announced on Thursday that China's National Medical Products Administration had accepted a new drug application for a combination therapy using fruquintinib and sintilimab to treat advanced renal cell carcinoma in patients who have failed prior tyrosine kinase inhibitor treatment.
Read moreHutchmed China upbeat on results from lung cancer trial
2nd Jun 2025 10:04
(Sharecast News) - Hutchmed China reported positive interim results from its phase three 'SACHI' trial on Monday, showing that the combination of savolitinib and osimertinib significantly improved progression-free survival (PFS) in patients with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC) and MET amplification, following progression on first-line EGFR inhibitor therapy.
Read moreHutchmed enrols patients for phase two savolitinib trial
22nd Apr 2025 08:46
(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for the registration phase of its phase two clinical trial, evaluating savolitinib in Chinese patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinoma.
Read moreHutchmed renal cell carcinoma trial meets primary endpoint
19th Mar 2025 10:55
(Sharecast News) - Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial evaluating the combination of fruquintinib and sintilimab as a second-line treatment for advanced renal cell carcinoma (RCC) in China had met its primary endpoint of progression-free survival.
Read moreHutchmed announces progress, hits milestone with lung cancer treatment
2nd Jan 2025 15:30
(Sharecast News) - Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment and a substantial divestment aimed at bolstering its core business strategy.
Read moreHutchmed to receive $10m milestone payment from partner Takeda
13th Dec 2024 09:36
(Sharecast News) - Hutchmed China announced on Friday that it would receive a $10m milestone payment from its partner Takeda, following a national reimbursement recommendation for 'Fruzaqla', or fruquintinib, in Spain.
Read moreHutchmed lung cancer therapy gets breakthrough designation in China
12th Dec 2024 11:27
(Sharecast News) - Hutchmed China announced on Thursday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to the combination of 'Orpathys', or savolitinib, and 'Tagrisso', or osimertinib.
Read more